2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Adverse Events, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3401 EVICTION 3: A randomized, Phase 2b/3, double-blinded study of IPN60340 versus placebo in combination with azacitidine and venetoclax in older/unfit patients with newly diagnosed acute myeloid leukemia

Abhishek Maiti, MBBS, Sylvain Garciaz, MD2, Jianming Wang3, Rajat Bannerji, MD, PhD4, Ivan Diaz-Padilla5, Pierre-Yves Dumas, MD, PhD6
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Aix-Marseille University, Marseille, France
3 Ipsen, Cambridge, Massachusetts, United States
4 Ipsen, Cambridge, Massachusetts, United States
5 Ipsen, Zug, Switzerland
6 Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France

Background and Significance:
Long-term outcomes for patients with newly diagnosed acute myeloid leukemia (ND-AML) unfit for intensive therapy remain poor, despite approval of the first line treatment azacitidine–venetoclax (Aza-Ven). IPN60340, formerly ICT01, is a first-in-class anti-BTN3A antibody. It is designed to harness immunotherapeutic benefit by activating γ9δ2 T cells which has been previously shown to drive graft-versus-leukemia effect after allogeneic stem cell transplantation.1 Preclinical studies, together with results from the phase 2 EVICTION trial (NCT04243499), have shown promising activity in patients with ND-AML who are ineligible for intensive chemotherapy (IC). In combination with Aza-Ven, patients receiving IPN60340 showed a high complete remission rate (CR) of 76%, encouraging survival, and no significant added toxicity beyond the known toxicity profile for Aza-Ven. EVICTION 3 (NCT07623187) will assess in a randomized trial whether the combination of IPN60340 plus Aza-Ven improves CR and overall survival (OS) vs standard of care Aza-Ven in patients ineligible for IC.

Study Design and Methods:
EVICTION 3 is a worldwide, multicenter, phase 2b/3, double-blinded, randomized, placebo-controlled trial in patients with ND-AML ineligible for IC. Eligible patients include those aged ≥75 years with an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2, or those aged <75 years with an ECOG performance status of 0–3 and a comorbidity which precludes treatment with IC.

In both phases 2b and 3 of the trial, patients will receive treatment in 28-day cycles. Patients will be randomized 1:1 to intravenous (IV) IPN60340 10 mg or placebo to be administered on Day 1 of each cycle in combination with Aza-Ven. In Cycle 1, Ven will be administered orally (400 mg), once daily on Days 1–28 and Aza will be administered subcutaneously or IV (75 mg/m2) daily, on Days 1–7. In Cycle 2+, responders (per 2022 European LeukemiaNet [ELN] criteria) may adjust Ven based on neutrophil and platelet count recovery. Treatment will continue until disease progression, unacceptable toxicity, patient withdrawal, or death. The trial aims to enroll approximately 90 participants in phase 2b and 450 participants in phase 3.

In phase 2b, the primary endpoint is CR, defined by ELN 2022 criteria, within the first 6 cycles of treatment. Analyses will be descriptive, with Bayesian interim monitoring. In phase 3, CR rate within the first 6 months is the primary endpoint and will be formally tested first, followed hierarchically by OS if differences in CR rates are significant. Secondary endpoints include OS, duration of CR, event-free survival and composite CR. Minimal residual disease will be assessed using multiparameter flow cytometry and molecular testing on bone marrow aspirate samples, at a central laboratory. Transfusion independence conversion rate, defined as a ≥56-day period without red blood cell, whole blood or platelet transfusion after treatment initiation in participants who required transfusion within 28 days before the first study dose, will also be assessed. These endpoints will be assessed through study end. For the primary and key secondary endpoints, results will be stratified by the following subgroups: TP53 mutational status (mutant versus wild-type) in both phases 2b and 3, with region (US versus outside the US) and age group (<75 years versus >75 years) included as additional stratification factors in phase 3 only. The study is expected to start on November 1, 2026, with completion anticipated in May 2032.

References:

Godder et al. Bone Marrow Transplant. 2007;39(12):751–7
Sylvain Garciaz, MD: Abbvie, Astellas, BMS-Celgene, Jazz Pharmaceuticals, Imcheck Therapeutics, Ipsen, JnJ and Servier - Consultancy (Includes expert testimony)